by MM360 Staff | Mar 7, 2026 | Myeloma News
Source: Pharmacy Times articles Post Content Read More
by Marisa Wexler, MS | Mar 6, 2026 | Myeloma News
The experimental therapy 177Lu-edotreotide outperformed the approved treatment everolimus in prolonging progression-free survival in people with pancreatic neuroendocrine tumors (PNETs), according to a new analysis of a Phase 3 clinical trial. ITM Isotope Technologies...
by MM360 Staff | Mar 6, 2026 | Myeloma News
Source: Pharmacy Times articles Post Content Read More
by Marisa Wexler, MS | Mar 5, 2026 | Myeloma News
A committee of the European Medicines Agency (EMA) has recommended the approval of Ipsen‘s tovorafenib for the treatment of pediatric low-grade glioma (pLGG). If authorized by the European Commission, the therapy would become a new targeted option for children 6...
by Marisa Wexler, MS | Mar 4, 2026 | Myeloma News
A low dose of alnodesertib added to standard chemotherapy significantly reduced the likelihood of disease progression among people with platinum-resistant high-grade serous ovarian carcinoma (HGSOC) in an early clinical trial. Findings from the Phase 2a study...
by Jacob Harney, PhD | Mar 3, 2026 | Myeloma News
March is Myeloma Action Month (MAM), and organizations around the world are participating to support patients, families, and caregivers who live with myeloma. This year, the International Myeloma Foundation (IMF) is inviting members of the myeloma community to...
